Anti-p-Tau181 antibody as well as preparation method and application thereof

Through the preparation of anti-p-Tau181 antibodies, the problem of lack of specific binding substances in Alzheimer's disease is solved, and specific detection and treatment of Alzheimer's disease is realized, which improves Alzheimer's disease and improves Alzheimer's disease. The cognitive function of disease cells and animal models has high clinical application value.

CN118909107AActive Publication Date: 2024-11-08SHANDONG LIFEI BIOLOGICAL IND CO LTD

Patent Information

Application Number
CN202410819634.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-24
Publication Date
2024-11-08
Estimated Expiration
2044-06-24

AI Technical Summary

Technical Problem

The existing Alzheimer's disease treatment cannot be effectively prevented or cured, and there is a lack of substances that specifically bind p-Tau181 to identify the disease, which makes it difficult to effectively deal with neurofibrillary tangles formed by Tau protein aggregation.

Method used

Using the preparation method of anti-p-Tau181 antibodies, monoclonal antibodies that specifically bind to p-Tau181 were obtained through immune response, cell fusion and cell screening, and were used to detect and treat Alzheimer's disease.

Benefits of technology

The specific detection and potential treatment of Alzheimer's disease have been achieved. By specifically binding to p-Tau181, the cognitive function of Alzheimer's disease cells and animal models has high clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909107A_ABST
    Figure CN118909107A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of monoclonal antibodies, and particularly discloses an anti-p-Tau181 antibody as well as a preparation method and application thereof. The preparation method of the anti-p-Tau181 antibody comprises the following steps: taking a section of p-Tau181 polypeptide IPAKTPPAPK (pT) PPSSGEPPK as an immunogen, and injecting the immunogen into the body of an experimental animal to carry out immune reaction, so as to obtain splenic lymphocytes of the experimental animal; carrying out mixed culture on myeloma cells and splenic lymphocytes to obtain fusion cells; the fusion cells are cultured, supernate is obtained for ELISA detection, polypeptide for detection is p-Tau181 polypeptide, hybridoma cell strains with the detection result being positive are taken and subjected to reverse screening through p-Tau217 polypeptide, p-Tau231 polypeptide and t-tau protein, positive clones which react to the p-Tau181 polypeptide and do not react to the p-Tau217 polypeptide, the p-Tau231 polypeptide and the t-tau protein are screened, cloning screening is carried out for multiple times, and the hybridoma cell strains with the detection result being positive are obtained. The hybridoma cell strain capable of secreting the antibody each time is obtained, and the antibody secreted by the hybridoma cell strain is the anti-p-Tau181 antibody. The anti-p-Tau181 antibody can be specifically combined with p-Tau181, so that the anti-p-Tau181 antibody can be used for detecting the Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the technical field of monoclonal antibodies, and specifically relates to an anti-p-Tau181 antibody and a preparation method and application thereof. Background Art

[0002] Tau is a microtubule-associated protein that can interact with other tubulins under normal physiological conditions, promote microtubule assembly, and regulate microtubule stability and dynamic properties. However, in certain pathological conditions, Tau protein may be modified, mainly through phosphorylation, which may produce abnormal aggregates that are toxic to neurons. When Tau protein is post-translationally hyperphosphorylated, it detaches from microtubules, leading to its self-aggregation and microtubule disintegration.

[0003] Alzheimer's disease (AD) is a neurodegenerative disease that seriously affects the health of the elderly. Its pathological characteristics are the accumulation of amyloid-β (Aβ) into plaques outside cells and the accumulation of hyperphosphorylated Tau into neurofibrillary tangles inside neurons. Although most drug trials for AD target Aβ or pathways related to Aβ, such as β- and γ-secretase cleavage, Tau protein has received increasing attention as another important target. Current treatments for AD can only alleviate symptoms but cannot prevent or cure the disease. Neurofibrillary tangles formed by Tau protein aggregation are one of the defining characteristics of AD, making Tau an attractive therapeutic target. The current drug strategies targeting tau protein can be summarized as inhibiting Tau aggregation, inhibiting Tau phosphorylation, reducing Tau levels and Tau immunity. There are many Tau-specific monoclonal antibodies in clinical trials. The phosphorylation product of threonine 181 (p-Tau181), which increases in vivo in the early stages of Alzheimer's disease, is the most widely used p-Tau biomarker in clinical practice. Substances that can specifically bind to p-Tau181 are needed to identify Alzheimer's disease. Summary of the invention

[0004] In view of the current need for a substance that can specifically bind to p-Tau181 to identify Alzheimer's disease, the present application proposes an anti-p-Tau181 antibody and a preparation method and application thereof. To this end, the present application adopts the following technical solution.

[0005] In a first aspect, the present application proposes a method for preparing an anti-p-Tau181 antibody, and adopts the following technical solution.

[0006] A method for preparing an anti-p-Tau181 antibody, the preparation method comprising: Immunization step: using a segment of p-Tau181 polypeptide IPAKTPPAPK(pT)PPSSGEPPK as an immunogen, injecting the immunogen into an experimental animal for immune response, and obtaining spleen lymphocytes of the experimental animal; Cell fusion step: taking myeloma cells and the spleen lymphocytes for mixed culture to obtain fusion cells; adding culture medium to the fusion cells for culture to obtain primary culture medium; Cell screening step: obtaining the supernatant of the initial culture solution for ELISA detection, the polypeptide used for detection is p-Tau181 polypeptide, taking the hybridoma cell line with a positive test result for counter-screening with p-Tau217 polypeptide, p-Tau231 polypeptide and t-tau protein, screening positive clones that react to the p-Tau181 polypeptide and have no reaction to p-Tau217 polypeptide, p-Tau231 polypeptide and t-tau protein, performing multiple cloning screenings to obtain a hybridoma cell line that can secrete antibodies each time, and the antibody secreted by the hybridoma cell line is the anti-p-Tau181 antibody.

[0007] By adopting the above technical solution, the hybridoma cell line can secrete the anti-p-Tau181 antibody, and the anti-p-Tau181 antibody can specifically bind to p-Tau181, so it can be used to detect Alzheimer's disease. In the cell fusion step, myeloma cells and spleen lymphocytes are mixed at a ratio of 5:1 to 10:1.

[0008] A preferred embodiment of the method for preparing the anti-p-Tau181 antibody is that the method further comprises cell culture and monoclonal antibody purification steps: The obtained hybridoma cell line is amplified and cultured, and the liquid after the amplification and culture is collected and treated with an ammonium sulfate solution to obtain a precipitate. The precipitate is dissolved in PBS and purified to obtain the anti-p-Tau181 antibody.

[0009] By adopting the above technical scheme, a larger amount of anti-p-Tau181 antibodies can be obtained.

[0010] A preferred embodiment of the method for preparing the anti-p-Tau181 antibody is that the immunization step specifically comprises: The p-Tau181 polypeptide and the immune adjuvant squalene are mixed at a mass ratio of 1: (2.5-3) to obtain an immune reagent, and multiple BALB / c mice aged 6-8 weeks are immunized for the first time by subcutaneous injection, and the injection dose of the first immune reagent is 40-60 μg / mouse; after an interval of 10-20 days, a second immunization is performed; the second immunization is as follows: the p-Tau181 polypeptide and the immune adjuvant squalene are mixed at a mass ratio of 1: (2.5-3), and the mixture is injected into the body of the mice after the first immunization by subcutaneous injection, and the injection dose of the second immune reagent is 40-60 μg / mouse; After the second immunization, 5-10 days later, the blood of each mouse was collected to detect the antibody titer in the serum: first, the multi-well ELISA plate was coated with 5-15μg / ml p-Tau181 polypeptide for 20-30h, and then the multi-well ELISA plate was blocked with 0.5%-1.5% bovine serum albumin at 36℃-38℃ for 0.5h-1.5h, and then various dilution multiples of non-immune mouse serum and secondary immunized mouse serum were added to each well and incubated at 36℃-38℃ for 0.5-1.5h, and then HRP-labeled secondary antibody was added and incubated at 36℃-38℃ for 0.5-1.5h, and then TMB substrate solution was added, and the reaction was carried out at room temperature in the dark for 10-20min, and finally sulfuric acid was used to terminate the reaction, and the OD value at 450nm was read to screen out the BALB / c mice with the highest immune titer P / N value.

[0011] By adopting the above technical scheme, the experimental mice acquired the ability to be immune to p-Tau181, and their spleen lymphocytes could secrete anti-p-Tau181 antibodies. This scheme also screened out mice that could stably secrete anti-p-Tau181 antibodies.

[0012] In a second aspect, the present application also proposes an anti-p-Tau181 antibody and adopts the following technical solution.

[0013] An anti-p-Tau181 antibody, wherein the VH gene sequence encoding the anti-p-Tau181 antibody is: AACCACCTTTTAGGAACTGGCGGTGTCCACTCCCAGGTCCAACTGCAGCAACCTGGGTCTGAGCTGGTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACATTCACCAGCTACTGGATGCACTGGGTGAAACAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAAATATTTATCCTGGTAGTGGTAGTACTCACTACGATGAAAAGTTC AGGAACAAGGCCACACTGACTGTAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTACAAGAGTAGTGGGAGACTACTGGGGCCAAGGCAGCACTCTCACAGTCTCCTCCGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAACTCCATTGTTATCCT.

[0014] By adopting the above technical solution, the anti-p-Tau181 antibody has the property of specifically binding to p-Tau181. Wherein, VH is the H chain (heavy chain) variable region.

[0015] A preferred embodiment of the anti-p-Tau181 antibody is that the VL gene sequence encoding the anti-p-Tau181 antibody is: GTTGACATTGATGACATTGAGGTCACCCAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCC AGACTCCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGAGCGTACACGTC.

[0016] By adopting the above technical solution, the VH sequence and VL sequence of the anti-p-Tau181 antibody are the positions binding to anti-p-Tau181, and the anti-p-Tau181 antibody has the property of specifically binding to p-Tau181. Among them, VL is the L chain (light chain) variable region.

[0017] On the third aspect, the present application also proposes an application of the anti-p-Tau181 antibody and adopts the following technical solution.

[0018] One application of the anti-p-Tau181 antibody is that the anti-p-Tau181 antibody is used to improve N2a cell damage induced by Aβ25-35.

[0019] By adopting the above technical solution, the application field of the anti-p-Tau181 antibody is improved.

[0020] Another application of the anti-p-Tau181 antibody is that the anti-p-Tau181 antibody is used to improve the cognitive function of OA-induced Alzheimer's disease (AD) rats.

[0021] By adopting the above technical scheme, the anti-p-Tau181 antibody can be used to improve the cognitive function of Alzheimer's disease animals, and also has the prospect of further clinical trials to improve the cognitive function of Alzheimer's disease patients.

[0022] In the application of the anti-p-Tau181 antibody, the cognitive function is spatial learning and memory ability.

[0023] By adopting the above technical scheme, the anti-p-Tau181 antibody has the prospect of further clinical trials to improve the spatial learning and memory abilities of patients with Alzheimer's disease.

[0024] In summary, the anti-p-Tau181 antibody and its preparation method and application of the present application have the following beneficial effects: Through immune response, cell fusion and cell screening, a hybridoma cell line is obtained that can secrete the anti-p-Tau181 antibody. Further, through cell culture and monoclonal antibody purification of the hybridoma cell line, the anti-p-Tau181 monoclonal antibody can be industrially produced. The anti-p-Tau181 antibody can specifically bind to p-Tau181 and can therefore be used to detect Alzheimer's disease.

[0025] Administration of the anti-p-Tau181 monoclonal antibody to AD cells and animal models can improve the viability of AD cells and the behavior and ability of AD rats. The monoclonal antibody of the present application has a high clinical application value in the detection, prevention, and treatment of AD. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is a bar chart comparing the titers of mouse immune response serum in Example 1.

[0027] Figure 2 This is the electrophoresis diagram of the VH and VL genes of the anti-p-Tau181 monoclonal antibody retrieved in Example 1.

[0028] Figure 3 This is the electrophoresis diagram for purity identification of the anti-p-Tau181 monoclonal antibody in Example 2.

[0029] Figure 4 This is a graph showing the affinity results of the anti-p-Tau181 antibody and p-Tau181 antigen in Example 2.

[0030] Figure 5 This is a graph showing the results of evaluating the protective effect of anti-Tau antibodies on Aβ25-35-induced PC12 cells in Example 3.

[0031] Figure 6 This is a diagram showing the test results of the water maze experiment in Example 3 for evaluating the spatial learning and memory abilities of rats.

[0032] Figure 7 The Y-maze test of Example 3 was used to track the latitudinal memory function test and compare the results. DETAILED DESCRIPTION

[0033] Example 1: Preparation of monoclonal antibodies that specifically recognize the phosphorylation site of p-Tau181 1. Immunogen The immunogen is IPAKTPPAPK(pT)PPSSGEPPK, which is a p-Tau181 polypeptide. The polypeptides used in this application are all synthesized by Sangon Biotech Co., Ltd.

[0034] 2. Mouse Immunization Five 6-8 week old BALB / c mice were used as experimental subjects, one of which was not injected with the immunogen as a blank reference. The p-Tau181 polypeptide was mixed with the immune adjuvant squalene at a mass ratio of 1:2.8, and four 6-8 week old BALB / c mice were immunized by subcutaneous injection, with an immunization dose of 50 μg / mouse. After two weeks, the second immunization was performed with the same method and dose. After two immunizations, tail blood was collected and the serum titer was determined by gradient dilution by ELISA method. Whether to boost immunization was determined based on the results. In this embodiment, two immunizations were performed.

[0035] One week after the last immunization, blood was collected from 5 mice, and the antibody titers in 5 serum samples were tested: 96-well ELISA plates were first coated with 10 μg / ml p-Tau181 peptide at 4°C for 24 h, and then blocked with 1% (wt) BSA (bovine serum albumin) at 37°C for 1 h. Figure 1 Then, 5 serum samples diluted 1000, 3×1000, 32×1000, 33×1000, 34×1000, 35×1000, 36×1000, and 2×36×1000 were added and incubated at 37°C for 1 hour, followed by the addition of HRP (horseradish peroxidase) labeled secondary antibody and incubation at 37°C for 1 hour, and then TMB (tetramethylbenzidine) substrate solution was added, and the reaction was carried out at room temperature in the dark for 15 minutes, and finally 2M sulfuric acid was used to terminate the reaction, and the OD value at 450nm was read. The highest dilution factor with P / N ≥ 2.1 was taken as the titer of the serum. Results are shown in Figure 1 , Figure 1 Part A shows that after immunization, all four mice produced corresponding immune titers, among which the immune titer P / N value (OD value of immune mice / OD value of non-immunized mice) of mouse 4 was the highest at the same dilution (e.g. Figure 1 Therefore, mouse 4 was selected as the subject of the next experiment.

[0036] 3. Cell Fusion Mouse 4 with the highest P / N value of immune titer was killed by cervical dislocation and immersed in 75% alcohol for 5 minutes for sterilization. Mouse 4 was fixed on a foam board with a pin, the abdominal skin was cut open, the abdominal cavity was opened, the fat and connective tissue on the surface of the spleen were peeled off, and the surface of the spleen was rinsed with modified Eagle medium (Dulbecco's Modified Eagle Medium, DMEM). A 200-mesh cell sieve was placed in a plate and moistened with 10 mL of DMEM medium. The spleen was pressed with a syringe plug, gently crushed, and ground clockwise. The cells were collected in a 50 mL centrifuge tube and centrifuged at 1500 r / min for 3 minutes at room temperature, and the supernatant was discarded. 5 mL of red blood cell lysis buffer placed in advance at room temperature was added to remove cell debris, and then 5 mL of DMEM medium was added. After mixing, the mixture was centrifuged at 1500 r / min for 3 minutes at room temperature, and the supernatant was discarded to obtain the spleen lymphocytes of mouse 4.

[0037] SP2 / 0 cells (mouse myeloma cells) were centrifuged at 1500r / min for 3min at room temperature, and the supernatant was discarded. SP2 / 0 cells and mouse 4 spleen lymphocytes were mixed in a 50mL centrifuge tube at a ratio of 8:1, and 10mL DMEM medium was added. Centrifuge at 1500r / min for 3min at room temperature. After discarding the supernatant, the following operations were performed in a 37℃ water bath: 1mL of 37℃ preheated polyethylene glycol 1500 (PEG1500) was slowly dripped into the centrifuge tube, and oscillated while adding, and then 1mL of DMEM medium was added and oscillated for 1min. Subsequently, 8mL of DMEM medium was added to terminate the fusion, and the mixture was centrifuged at 1500r / min for 3min, and the cell supernatant was discarded. The fused cells were evenly mixed in a medium containing a high concentration of nucleotide precursor substances, and then dripped into a 96-well cell culture plate to which feeder cells had been added.

[0038] 4. Cell Screening When the cells in the culture plate grow to a medium size, the cell supernatant is aspirated for ELISA detection, and the peptide used for detection is p-Tau181 polypeptide. After an interval of two days, the test is performed again, and the hybridoma cell lines with positive results in both tests are taken for counter-screening with p-Tau217 polypeptide, p-Tau231 polypeptide and t-tau protein. The positive clones that react to p-Tau181 polypeptide and have no reaction to p-Tau217 polypeptide, p-Tau231 polypeptide and t-tau protein are cloned three times (differential screening is performed for each cloning test) to obtain hybridoma cell lines that can stably secrete antibodies. Finally, the 2-1E cell line (hybridoma cell line) against p-Tau181 polypeptide is obtained.

[0039] 5. Cell Culture The stable 2-1E cell line was expanded and cultured in a carbon dioxide incubator, and then transferred from a 96-well plate to a 24-well plate, a 6-well plate, and a 10 cm cell plate. The cells in the cell plate were then collected and injected into the mouse peritoneal cavity, and ascites containing monoclonal antibodies (anti-p-Tau181 antibodies) were extracted from the mouse peritoneal cavity 7 to 10 days later.

[0040] 6. Monoclonal antibody purification The mouse ascites containing monoclonal antibodies was treated with 50% saturated ammonium sulfate solution. The precipitate was then dissolved in PBS (phosphate buffered saline) and purified using a Protein A column to obtain purified monoclonal antibodies. The obtained monoclonal antibodies were PCR amplified, and the PCR products were sent to the company for sequencing to obtain the sequence.

[0041] 7. Results and Analysis 7.1 VH and VL gene retrieval Figure 2The electrophoresis diagram of the PCR product shows that the anti-p-Tau181 antibody VH and VL genes (500 bp) were successfully retrieved.

[0042] 7.2 Gene sequencing results After sequencing by a gene company, the VH and VL gene sequences of the anti-p-Tau181 antibody were obtained as follows: VH Seq: AACCACCTTTTAGGAACTGGCGGTGTCCACTCCCAGGTCCAACTGCAGCAACCTGGGTCTGAGCTGGTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACATTCACCAGCTACTGGATGCACTGGGTGAAACAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAAATATTTATCCTGGTAGTGGTAGTACTCACTACGATGAAAAGTT CAGGAACAAGGCCACACTGACTGTAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTACAAGAGTAGTGGGAGACTACTGGGGCCAAGGCAGCACTCTCACAGTCTCCTCCGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAACTCCATTGTTATCCT AA1: NHLLGTGGVHSQVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSGSTHYDEKFRNKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRVVGDYWGQGSTLTVSSAKTTPPSVYPLAPGSAAQTNSIVI VL Seq: GTTGACATTGATGACATTGAGGTCACCCAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCC AGACTCCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGAGCGTACACGTC AA2: VDIDDIEVTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRSVHV The variable regions of the heavy and light chains of mouse antibodies, namely the VH and VL regions, were compared using GENBANK (a DNA sequence database established by the National Center for Biotechnology Information of the United States).

[0043] Example 2: Anti-p-Tau181 monoclonal antibody protein identification 1. Specificity identification of anti-p-Tau181 monoclonal antibodies The p-Tau181 polypeptide, p-Tau217 polypeptide, p-Tau231 polypeptide and t-Tau protein (all at 5 ng / μL) were coated with ELISA plates, 50 μL of the cell supernatant of the monoclonal antibody to be tested (containing the monoclonal antibody produced by the 2-1E cell line obtained in Example 1) was added, incubated at 37°C for 1 hour, washed 3 to 5 times with PBST (phosphate buffered saline), and a 1:1000 diluted HRP (horseradish peroxidase) labeled goat anti-mouse IgG secondary antibody (100 μL / well) was added. After incubation at 37°C for 45 minutes, the plate was washed 3 to 5 times with PBST, 100 μL / well TMB (tetramethylbenzidine) colorimetric solution was added, and the plate was protected from light for 15 minutes. 2M sulfuric acid 50 μL / well was added to terminate the reaction, and the OD450nm value of each detection well was read. The OD450nm value of each well was judged as positive based on P / N ≥ 2.1. The results are shown in Table 1.

[0044] The identification results in Table 1 show that the monoclonal antibody produced by the 2-1E cell line is a specific antibody against the p-Tau181 polypeptide, and does not react with the p-Tau217, p-Tau231 polypeptides and t-Tau protein.

[0045] Table 1. Specificity identification of anti-p-Tau181 monoclonal antibodies antigen OD value (solution absorbance) P / N Negative control 0.054 / p-Tau181 peptide 1.898 35.148 p-Tau217 peptide 0.051 1 p-Tau231 peptide 0.050 1 t-Tau protein 0.049 1 The results in Table 1 indicate that the monoclonal antibody produced by the 2-1E cell line has specific binding ability to the p-Tau181 polypeptide, and the monoclonal antibody is named anti-p-Tau181 antibody or anti-p-Tau181 monoclonal antibody.

[0046] 2. Purity Identification of Anti-p-Tau181 Monoclonal Antibodies Prepare 5% (wt) separation gel and 15% (wt) concentration gel, load the purified anti-p-Tau181 antibody and perform electrophoresis under constant voltage conditions. Stop electrophoresis when bromophenol blue reaches 1 cm from the bottom edge of the separation gel. Remove the film and place it in Coomassie brilliant blue staining solution for 30 minutes, and finally decolorize it 2 to 3 times with decolorizing solution until the background is colorless. Scan the film with a scanner and save the image, and analyze the antibody purity with Gelpro32 software.

[0047] Purity identification results Figure 3 There are obvious specific bands at 25kD and 60kD, without other mixed bands. 25kD and 60kD are the light chain and heavy chain bands, and the total content of light chain and heavy chain (antibody purity) is 96.83%, indicating that the obtained antibody has a high purity.

[0048] 3. Determination of affinity constant of anti-p-Tau181 monoclonal antibody This application uses biomembrane interferometry (BLI) to detect the affinity and kinetic parameters of the binding between antibodies and antigens (p-Tau181 polypeptides). The antibody is solidified on the sensor surface using a SA sensor, and then reacted with gradient diluted antigens. The information on the molecular interaction is obtained by analyzing the changes in surface light interference. For specific operating methods, please refer to the instrument manual.

[0049] Affinity test results Figure 4 As shown in Table 2, the affinity of the anti-p-Tau181 antibody to the p-Tau181 antigen is 1.98 nM, indicating that the anti-p-Tau181 monoclonal antibody prepared in Example 1 has a higher affinity to the antigen p-Tau181.

[0050] Table 2. Affinity testing of anti-p-Tau181 monoclonal antibodies Antibody kon(1 / Ms) koff(1 / s) KD(M) 2-1E 2.02E+006 3.99E-003 1.98E-009 Example 3: Application of anti-p-Tau181 antibody 1. Protective effect of anti-Tau antibody on N2a cells induced by Aβ25-35 1.1 Cell culture Mouse neuroblastoma cells N2a were cultured in DMEM medium containing 10% (wt) fetal bovine serum and 1% (wt) antibiotics (penicillin 100 IU / ml + streptomycin 100 μg / ml) at 37°C in an incubator with 5% CO2, and cells in the logarithmic growth phase were collected for experiments.

[0051] 1.2 Cell grouping and treatment N2a cells were divided into three groups: blank control group (N2a cells were cultured normally without treatment), AD group (N2a cells were cultured with 20 μM Aβ25-35 for 24 hours), and anti-p-Tau181 antibody group (N2a cells were treated with Aβ25-35 and anti-p-Tau181 antibody).

[0052] AD group: N2a cells were cultured at 10 4 / mL concentration was inoculated in a 96-well plate. Aβ25-35 at a concentration of 20 μM was added to the cells and incubated for 24 h.

[0053] Anti-p-Tau181 antibody group: N2a cells were pretreated with 20 μM Aβ25-35 for 24 h, and then 20 μM anti-p-Tau181 antibody was added and incubated for another 24 h.

[0054] 1.3 Cell proliferation assay N2a cells were cultured in 96-well plates according to the above grouping, and 50% (wt) trichloroacetic acid was added to each well, incubated at 4°C for 1 hour, and then 50 μL of 0.4% (wt) SRB solution was added after drying for 15 minutes, and then rinsed with a small amount of 1% (wt) acetic acid solution 2 to 3 times. After drying, 100 μL of 10 mM Tris base solution was added to each well to dissolve the crystals, and the absorbance value (OD value) of each well was measured at a wavelength of 540 nm using an enzyme-linked immunosorbent assay.

[0055] 2. Effect of anti-p-Tau181 antibody on cognitive function improvement in Aβ25-35-induced AD rats 2.1 Experimental animals Male Sprague-Dawley (SD) rats (n=15), 8 weeks old and weighing 160-190 g, were housed in sterile, independently ventilated isolation cages with laminar air flow purification rooms, maintained at a constant temperature (26-28°C) and humidity (relative humidity 40%-60%), and feed, water, and bedding were sterilized before use.

[0056] 2.2 AD rat model construction and grouping Establishment of AD rat model induced by Aβ25-35 1 mg Aβ25-35 was dissolved in 200 μL sterile saline, sealed and placed in a 37°C cell culture incubator for 96 h to form Aβ25-35 aggregates.

[0057] The rats were divided into three groups: a blank control group (no treatment), an AD model group (AD rat model was established by intracerebral injection of Aβ25-35 aggregates), and an anti-p-Tau181 antibody group (AD rat model was established by intracerebral injection of Aβ25-35 aggregates and treated with anti-p-Tau181 antibodies).

[0058] AD model rats: After intraperitoneal injection of 4% sodium pentobarbital for anesthesia, the rats were fixed in a flat skull position using a brain stereotaxic instrument. The dorsal part of the right hippocampus was determined to be 3.8 mm behind the right anterior bregma, 2.5 mm beside the midline, and 3.0 mm below the skull surface. Aβ25-35 was slowly injected with a 1 μL microsyringe within 5 minutes, and the needle was retained for 10 minutes. After surgery, 50,000 units of penicillin sodium salt were injected intramuscularly once a day for 3 consecutive days.

[0059] Rats in the anti-p-Tau181 antibody group: Some AD model rats were intraperitoneally injected with 10 mg / kg anti-p-Tau181 antibody daily for 28 consecutive days.

[0060] 2.3 Water maze test 2.3.1 Experimental setup Morris water maze is a circular pool with a diameter of 100 cm, a depth of 50 cm, a water depth of 30 cm, a water temperature of (24 ± 2) ° C, and a layer of plastic foam crumbs on the water surface. The pool is divided into four quadrants at four equidistant points on the pool wall. A platform is placed in the center of the third quadrant. The platform is colorless and transparent, with a diameter of 10 cm and a height of 28 cm. The platform is submerged 2 cm below the water surface. The reference objects around the pool remain unchanged.

[0061] 2.3.2 Positioning navigation experiment Each group of rats were placed in the water with their heads facing the pool wall, and the placement position was randomly selected from one of the four starting positions of east, west, south, and north. The video was recorded at the same time as the rat entered the water, and the time (s) from entering the water to finding the underwater platform was recorded (escape latency). If the platform position was still not found within 90s, the rat was guided to the platform position, and the time was recorded as 90s. After the rat stayed on the platform for 15s, it was removed from the pool and wiped dry (if necessary, the rat was placed under a 150W incandescent lamp for 5min and returned to the cage). Each rat was trained 4 times a day, with an interval of 15-20min, and the average value was taken as the score for the day. The training lasted for 5 days.

[0062] 2.3.3 Space Exploration Experiment On the second day after the end of the positioning navigation experiment training, the platform was removed and a 90-second spatial exploration training was started. The rats were placed in the water from the first quadrant. The number of times the rats crossed the original platform within 90 seconds was recorded.

[0063] 2.4Y maze test The floor and walls of the three-arm maze (40 cm high and 4 cm wide) were made of polyethylene plastic. Rats were placed in one of the arms and allowed to move freely in the maze for 8 minutes. The number of times the rat entered the maze was counted after all its front paws touched the ground. The rat entered three different arms in sequence (e.g., ⅠⅡⅢ, ⅠⅢⅡ, ⅡⅢⅠ, ⅡⅠⅢ, ⅢⅠⅡ, ⅢⅡⅠ) as an alternation. The maze was cleaned with 10% ethanol solution after each trial. Spontaneous alternation rate (%) = (spontaneous alternation number / [total number of arm entries-2]) × 100.

[0064] 3. Experimental results 3.1MTT Results Figure 5 The results showed that compared with the blank control group, the survival rate of N2a cells in the AD group was significantly decreased (p<0.05); compared with the AD group, the survival rate of N2a cells in the anti-p-Tau181 antibody group was significantly increased (p<0.05). This indicates that the anti-p-Tau181 antibody has an ameliorative effect on N2a cell damage induced by Aβ25-35.

[0065] 3.2 Water maze test results Figure 6 The spatial learning and memory ability of rats was evaluated by water maze experiment. Compared with the blank control group, AD model rats had obvious memory defects in learning performance, which was manifested as prolonged escape latency and reduced number of times passing through the platform; compared with the AD group, anti-p-Tau181 antibody treatment significantly increased the number of times passing through the platform and reduced escape latency, reflecting that the spatial memory of AD model rats was improved.

[0066] 3.3Y maze test results The Y-maze test was used to track the latitudinal memory function test and compare the results with reference Figure 7 . Compared with the control group, the number of spontaneous alternations and total arm entries of rats in the AD model group were significantly reduced (p<0.05). In addition, compared with the OA group, the number of spontaneous alternations and total arm entries in the antibody group increased significantly (p<0.05). The results showed that the p-Tau181 antibody had an improving effect on the behavioral disorders of AD rats.

[0067] The above are only some embodiments of the present application, and the protection scope of the present application is not limited to the above embodiments. For ordinary technicians in this technical field, some improvements and modifications without departing from the creative design of the present application should also fall within the protection scope of the present application.

Claims

1. A method for preparing an anti-p-Tau181 antibody, characterized in that: The preparation method comprises: Immunization step: using a segment of p-Tau181 polypeptide IPAKTPPAPK(pT)PPSSGEPPK as an immunogen, injecting the immunogen into the body of an experimental animal for immune response, and obtaining spleen lymphocytes of the experimental animal; Cell fusion step: taking myeloma cells and the spleen lymphocytes for mixed culture to obtain fusion cells; adding culture medium to the fusion cells for culture to obtain primary culture medium; Cell screening step: obtaining the supernatant of the initial culture solution for ELISA detection, the polypeptide used for detection is p-Tau181 polypeptide, taking the hybridoma cell line with a positive test result for counter-screening with p-Tau217 polypeptide, p-Tau231 polypeptide and t-tau protein, screening positive clones that react to the p-Tau181 polypeptide and have no reaction to p-Tau217 polypeptide, p-Tau231 polypeptide and t-tau protein, performing multiple cloning screenings to obtain a hybridoma cell line that can secrete antibodies each time, and the antibody secreted by the hybridoma cell line is the anti-p-Tau181 antibody.

2. The method for preparing an anti-p-Tau181 antibody according to claim 1, characterized in that: The preparation method also includes cell culture and monoclonal antibody purification steps: The obtained hybridoma cell line is amplified and cultured, and the liquid after the amplification and culture is collected and treated with an ammonium sulfate solution to obtain a precipitate. The precipitate is dissolved in PBS and purified to obtain the anti-p-Tau181 antibody.

3. The method for preparing an anti-p-Tau181 antibody according to claim 1, characterized in that: The immunization step specifically includes: The p-Tau181 polypeptide and the immune adjuvant squalene are mixed at a mass ratio of 1: (2.5-3) to obtain an immune reagent, and multiple BALB / c mice aged 6-8 weeks are immunized for the first time by subcutaneous injection, and the injection dose of the first immune reagent is 40-60 μg / mouse; after an interval of 10-20 days, a second immunization is performed; the second immunization is as follows: the p-Tau181 polypeptide and the immune adjuvant squalene are mixed at a mass ratio of 1: (2.5-3), and the mixture is injected into the body of the mice after the first immunization by subcutaneous injection, and the injection dose of the second immune reagent is 40-60 μg / mouse; After the second immunization, 5-10 days later, the blood of each mouse was collected to detect the antibody titer in the serum: first, the multi-well ELISA plate was coated with 5-15μg / ml p-Tau181 polypeptide for 20-30h, and then the multi-well ELISA plate was blocked with 0.5%-1.5% bovine serum albumin at 36℃-38℃ for 0.5h-1.5h, and then various dilution multiples of non-immune mouse serum and secondary immunized mouse serum were added to each well and incubated at 36℃-38℃ for 0.5-1.5h, and then HRP-labeled secondary antibody was added and incubated at 36℃-38℃ for 0.5-1.5h, and then TMB substrate solution was added, and the reaction was carried out at room temperature in the dark for 10-20min, and finally sulfuric acid was used to terminate the reaction, and the OD value at 450nm was read to screen out the BALB / c mice with the highest immune titer P / N value.

4. An anti-p-Tau181 antibody, characterized in that The VH sequence encoding the anti-p-Tau181 antibody gene is: AACCACCTTTTAGGAACTGGCGGTGTCCACTCCCAGGTCCAACTGCAGCAACCTGGGTCTGAGCTGGTGAGGCCTGGAGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACATTCACCAGCTACTGGATGCACTGGGTGAAACAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAAATATTTATCCTGGTAGTGGTAGTACTCACTACGATGAAAAGTTC AGGAACAAGGCCACACTGACTGTAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTACAAGAGTAGTGGGAGACTACTGGGGCCAAGGCAGCACTCTCACAGTCTCCTCCGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAACTCCATTGTTATCCT.

5. The anti-p-Tau181 antibody according to claim 4, characterized in that The VL sequence encoding the anti-p-Tau181 antibody gene is: GTTGACATTGATGACATTGAGGTCACCCAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCC AGACTCCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGAGCGTACACGTC.

6. A use of the anti-p-Tau181 antibody according to any one of claims 1 to 5, characterized in that: The anti-p-Tau181 antibody is used to improve N2a cell damage induced by Aβ25-35.

7. A use of the anti-p-Tau181 antibody according to claim 6, characterized in that: The anti-p-Tau181 antibody is used to improve the cognitive function of OA-induced Alzheimer's disease rats.

8. A use of the anti-p-Tau181 antibody according to claim 7, characterized in that: The cognitive function is spatial learning and memory ability.

Citation Information

Patent Citations

  • Preparation method of monoclonal antibodies for detecting phosphorylated tau protein pairing

    CN112979800A

  • Hybridoma cell strain secreting anti-serine phosphorylated tau protein monoclonal antibody

    CN113005096A

Cited By

  • Hybridoma cell strain secreting anti-181-site threonine phosphorylated tau monoclonal antibody

    CN119432768A

  • Anti-p-Tau181 protein monoclonal antibody as well as preparation method and application thereof

    CN119899264A

  • A monoclonal antibody against p-Tau181 protein, its preparation method and application

    CN119899264B

  • Preparation of anti-p-Tau217 antibody and application of anti-p-Tau217 antibody in Alzheimer's disease detection kit

    CN120040585A

  • Preparation of anti-p-tau217 antibody and its application in alzheimer's disease detection kit

    CN120040585B